




Searching News Database: Centocor Ortho Biotech
HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
HSMN NewsFeed - 29 Apr 2011
Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
HSMN NewsFeed - 23 Feb 2011
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
HSMN NewsFeed - 1 Jun 2010
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
HSMN NewsFeed - 26 Jan 2010
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
HSMN NewsFeed - 25 Nov 2009
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
HSMN NewsFeed - 24 Nov 2009
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 15 Jul 2009
Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer
Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer
HSMN NewsFeed - 21 May 2009
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis